Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed EBITDA Margin for 6 consecutive years, with 7779.24% as the latest value for Q3 2023.

  • Quarterly EBITDA Margin fell 488860.0% to 7779.24% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 33218.0% through Jun 2024, down 3318371.0% year-over-year, with the annual reading at 41.66% for FY2023, 26294.0% up from the prior year.
  • EBITDA Margin for Q3 2023 was 7779.24% at Denali Therapeutics, down from 62.71% in the prior quarter.
  • The five-year high for EBITDA Margin was 62.71% in Q2 2023, with the low at 7002800.0% in Q1 2021.
  • Average EBITDA Margin over 5 years is 425093.29%, with a median of 1236.26% recorded in 2019.
  • The sharpest move saw EBITDA Margin tumbled -700121560bps in 2021, then soared 700262921bps in 2022.
  • Over 5 years, EBITDA Margin stood at 1236.26% in 2019, then surged by 49bps to 625.66% in 2020, then plummeted by -156bps to 1603.42% in 2021, then skyrocketed by 42bps to 937.11% in 2022, then tumbled by -730bps to 7779.24% in 2023.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 7779.24%, 62.71%, and 299.97% for Q3 2023, Q2 2023, and Q1 2023 respectively.